Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 13/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327446 | 1.00 | ATM (0.39) | ATMPYGLTOP2AMTNR1AMTNR1B | |
| SCHEMBL13299033 | 0.89 | EPHX2 (0.41) | ATMPYGLTOP2AKMT2A | |
| SCHEMBL13850674 | 0.89 | EPHX2 (0.41) | ATMPYGLTOP2AKMT2A | |
| SCHEMBL3327649 | 0.79 | TOP2A (0.38) | TOP2AMEN1TSHRKMT2A | |
| SCHEMBL4654051 | 0.79 | PYGL (0.68) | PYGL | |
| SCHEMBL4654053 | 0.79 | PYGL (0.68) | PYGL | |
| SCHEMBL3326627 | 0.78 | ATM (0.38) | ATMPYGLMTNR1AMTNR1BMEN1 | |
| SCHEMBL9489863 | 0.78 | MTNR1A (0.46) | ATMPYGLMTNR1AMTNR1BMEN1 | |
| SCHEMBL3328882 | 0.78 | PYGL (0.69) | PYGL | |
| SCHEMBL3328886 | 0.78 | PYGL (0.69) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137397-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-1658067-B1 | INDOLAMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1658069-B1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060211760-A1 | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211760-A1 | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity | PYGL, PYGM, PYGB | ATM 2821/4885PYGL 1/4885TOP2A 988/4885 |
| US-20100137397-A1 | Chemical Compounds | PYGL, PYGM, GYS2 | ATM 2986/4885PYGL 1/4885TOP2A 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.